Gastroenterology and Hepatology

Gastroenterology and Hepatology

By ReachMDMedicine
Download on the App Store

Gastroenterology and Hepatology episodes

  • Chairperson's Perspective: Innovative Approaches to IBS-C: Personalized Treatment for Better Outcomes
    Host: Darren Brenner, MD

    Irritable bowel syndrome with constipation (IBS-C) significantly impacts patients, not only with its physical symptoms of persistent constipation, abdominal pain, and bloating, but also through a considerable psychological and social burden. Do you know how to effectively treat IBS-C to increase your patients’ quality of life? Tune in for an overview of the latest data.

    0 min
  • FCS: Enhancing the Diagnosis
    Guest: Daniel Gaudet, MD, PhD

    There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

    4 min
  • Setting the Bar: Guideline-Recommended Treatment in Hypertriglyceridemia
    Guest: Børge G. Nordestgaard, MD, DMSc
    Guest: Kausik Ray, MBChB, MD, MPhil

    There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

    4 min
  • APOC3 Inhibition: A Novel Approach to Lowering TGs
    Guest: Børge G. Nordestgaard, MD, DMSc
    Guest: Kausik Ray, MBChB, MD, MPhil

    There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

    4 min
  • Latest Clinical Trial Outcomes and Breakthroughs for FCS
    Guest: Daniel Gaudet, MD, PhD
    Guest: Pam R. Taub, MD, FACC, FASPC

    There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

    4 min
  • SHTG: Defining the Unmet Clinical Need
    Guest: Pam R. Taub, MD, FACC, FASPC
    Guest: Kausik Ray, MBChB, MD, MPhil

    There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

    5 min
  • SHTG: Decoding the Latest Clinical Trial Outcomes
    Guest: Pam R. Taub, MD, FACC, FASPC
    Guest: Kausik Ray, MBChB, MD, MPhil

    There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

    5 min
  • Remnant Cholesterol: The Missing Link in ASCVD risk
    Guest: Børge G. Nordestgaard, MD, DMSc
    Guest: Kausik Ray, MBChB, MD, MPhil

    There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

    3 min
  • Targeting Mixed Hyperlipidemia with APOC3 Inhibition
    Guest: Pam R. Taub, MD, FACC, FASPC
    Guest: Kausik Ray, MBChB, MD, MPhil

    There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

    5 min
  • The Road Ahead: What's on the Horizon for FCS and SHTG Management
    Guest: Pam R. Taub, MD, FACC, FASPC
    Guest: Prof. Kausik Ray

    There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

    5 min